Colorado § 25-45-201 Legislative declaration

Colorado Statutes

§ 25-45-201 — Legislative declaration

Colorado § 25-45-201

Title 25Public

Art.Access to Treatments for Terminally Ill Patients

This text of Colorado § 25-45-201 (Legislative declaration) is published on Counsel Stack Legal Research, covering Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Colo. Rev. Stat. § 25-45-201 (2026).

Text

(1)For purposes of this part 2, the general assembly finds and determines that:

(a)Some public and private entities operating under federal standards for the protection of human subjects in research develop individualized investigational drugs, biological products, and devices that are unique and produced exclusively for use by an individual patient based on the patient's genetic profile, including individual gene therapy, antisense oligonucleotides, and individualized neoantigen vaccines; and

(b)A patient who has a life-threatening or severely debilitating illness may benefit from these individualized treatments.

(2)Therefore, the general assembly declares that, in accordance with the recommendation of the patient's treating physician and with the safeguards described in t

Free access — add to your briefcase to read the full text and ask questions with AI

(1) For purposes of this part 2, the
general assembly finds and determines that:

(a) Some public and private entities operating under federal standards for
the protection of human subjects in research develop individualized investigational
drugs, biological products, and devices that are unique and produced exclusively
for use by an individual patient based on the patient's genetic profile, including
individual gene therapy, antisense oligonucleotides, and individualized neoantigen
vaccines; and

(b) A patient who has a life-threatening or severely debilitating illness may
benefit from these individualized treatments.

(2) Therefore, the general assembly declares that, in accordance with the
recommendation of the patient's treating physician and with the safeguards
described in this part 2, a patient should have the right to try an individualized
investigational drug, biological product, or device, and the treating physician and
manufacturer that provides the individualized investigational drug, biological
product, or device, acting in accordance with this part 2, should be protected from
adverse consequences resulting from the patient's decision to try the individualized
investigational drug, biological product, or device.